JP2018519243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519243A5 JP2018519243A5 JP2017549616A JP2017549616A JP2018519243A5 JP 2018519243 A5 JP2018519243 A5 JP 2018519243A5 JP 2017549616 A JP2017549616 A JP 2017549616A JP 2017549616 A JP2017549616 A JP 2017549616A JP 2018519243 A5 JP2018519243 A5 JP 2018519243A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- cancer
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139189P | 2015-03-27 | 2015-03-27 | |
| GBGB1505305.1A GB201505305D0 (en) | 2015-03-27 | 2015-03-27 | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| US62/139,189 | 2015-03-27 | ||
| GB1505305.1 | 2015-03-27 | ||
| PCT/EP2016/056557 WO2016156202A1 (en) | 2015-03-27 | 2016-03-24 | Novel peptides and combination of peptides for use in immunotherapy against various tumors |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018140996A Division JP6742369B2 (ja) | 2015-03-27 | 2018-07-27 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
| JP2020087423A Division JP7217981B2 (ja) | 2015-03-27 | 2020-05-19 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
| JP2020091899A Division JP2020188769A (ja) | 2015-03-27 | 2020-05-27 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519243A JP2018519243A (ja) | 2018-07-19 |
| JP2018519243A5 true JP2018519243A5 (enExample) | 2019-04-11 |
| JP6882985B2 JP6882985B2 (ja) | 2021-06-02 |
Family
ID=53178247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549616A Expired - Fee Related JP6882985B2 (ja) | 2015-03-27 | 2016-03-24 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Country Status (19)
| Country | Link |
|---|---|
| US (52) | US9988432B2 (enExample) |
| EP (8) | EP3388077A1 (enExample) |
| JP (1) | JP6882985B2 (enExample) |
| KR (3) | KR20210043752A (enExample) |
| CN (2) | CN113480635A (enExample) |
| AR (4) | AR127116A2 (enExample) |
| AU (13) | AU2016239920B2 (enExample) |
| BR (1) | BR112017017289A2 (enExample) |
| CA (26) | CA3110160A1 (enExample) |
| CR (3) | CR20200471A (enExample) |
| EA (3) | EA201891699A3 (enExample) |
| GB (1) | GB201505305D0 (enExample) |
| MA (9) | MA41805A (enExample) |
| MX (1) | MX2017012427A (enExample) |
| PE (1) | PE20171442A1 (enExample) |
| SG (3) | SG11201706681VA (enExample) |
| TW (3) | TW202043258A (enExample) |
| UA (2) | UA124139C2 (enExample) |
| WO (1) | WO2016156202A1 (enExample) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| FI3273986T3 (fi) | 2015-03-27 | 2024-02-07 | Immatics Biotechnologies Gmbh | Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CN107810193B (zh) | 2015-05-06 | 2022-03-22 | 伊玛提克斯生物技术有限公司 | 用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架 |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520562D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520583D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520542D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520558D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520603D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520545D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| DE102016123859B3 (de) * | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| EP3565831A4 (en) * | 2016-12-29 | 2021-01-13 | Board Of Regents, The University Of Texas System | HLA RESTRICTED VCX / Y-PEPTIDES AND T-CELL RECEPTORS AND USES |
| CN110809580A (zh) * | 2017-01-24 | 2020-02-18 | 安贝科思生物制剂公司 | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 |
| PE20191248A1 (es) * | 2017-01-27 | 2019-09-18 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer |
| TWI796314B (zh) * | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
| EP3576764A4 (en) | 2017-02-03 | 2020-12-16 | The Medical College of Wisconsin, Inc. | KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CA3051062C (en) | 2017-02-28 | 2023-09-26 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| GB201704128D0 (en) * | 2017-03-15 | 2017-04-26 | Univ Swansea | Method and apparatus for use in diagnosis and monitoring of colorectal cancer |
| EP3609530A1 (en) * | 2017-04-10 | 2020-02-19 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| US11427614B2 (en) | 2017-04-10 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| CN119080881A (zh) | 2017-07-07 | 2024-12-06 | 伊玛提克斯生物技术有限公司 | 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物 |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| WO2019067887A1 (en) * | 2017-09-29 | 2019-04-04 | Spyryx Biosciences, Inc. | ENAC INHIBITOR PEPTIDES AND USES THEREOF |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR20250052472A (ko) | 2017-11-06 | 2025-04-18 | 이매틱스 바이오테크놀로지스 게엠베하 | 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법 |
| DE102017125888A1 (de) * | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| KR102267463B1 (ko) * | 2018-02-15 | 2021-06-21 | 코쿠리츠다이가쿠호진 아사히카와 이카다이가쿠 | 암 항원 펩티드 |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| EP3765071A4 (en) | 2018-03-12 | 2022-05-25 | The Children's Hospital of Philadelphia | METHODS AND COMPOSITIONS FOR USE OF TUMOR AUTOGENS IN ADOPTIVE IMMUNOTHERAPY |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3545967A1 (en) * | 2018-03-28 | 2019-10-02 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer immunization platform |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US12195769B2 (en) | 2018-06-19 | 2025-01-14 | Dsm Ip Assets B.V. | Lipolytic enzyme variants |
| SG11202012688UA (en) * | 2018-06-22 | 2021-01-28 | Merck Patent Gmbh | Dosing regimens for targeted tgf-b inhibition for use in treating biliary tract cancer |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) * | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| CN113301913A (zh) | 2019-01-06 | 2021-08-24 | 第二基因组股份有限公司 | 用于免疫疗法的源自微生物的肽和蛋白质 |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| MX2021013588A (es) | 2019-05-08 | 2022-02-11 | Medigene Immunotherapies Gmbh | Células t genomodificadas. |
| WO2020232408A1 (en) * | 2019-05-15 | 2020-11-19 | Genocea Biosciences, Inc. | Treatment methods |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN110567861B (zh) * | 2019-09-09 | 2021-12-21 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法 |
| CN110804643B (zh) * | 2019-10-29 | 2022-06-21 | 同济大学 | 一种体外评价卡介苗对中性粒细胞活性影响的方法 |
| JP2023504659A (ja) | 2019-12-03 | 2023-02-06 | ニューボーゲン，インコーポレイティド | 腫瘍細胞ワクチン |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) * | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022047325A1 (en) * | 2020-08-31 | 2022-03-03 | The Trustees Of Columbia University In The City Of New York | Targeting of tgm4 to treat prostate cancer |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| US11891427B2 (en) | 2020-09-29 | 2024-02-06 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers |
| WO2022125874A2 (en) * | 2020-12-11 | 2022-06-16 | Berkeley Lights, Inc. | Methods for identification of exchangeable mhc binding peptides and methods of use thereof |
| CA3202176A1 (en) * | 2020-12-14 | 2022-06-23 | Michael Steven ROONEY | Tissue-specific antigens for cancer immunotherapy |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| AU2022233285A1 (en) | 2021-03-09 | 2023-10-19 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
| CA3211645A1 (en) * | 2021-03-12 | 2022-09-15 | Erika VON EUW | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| US20240317816A1 (en) * | 2021-06-04 | 2024-09-26 | Genevive, Inc. | Peptides for immunotherapy |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| EP4419545A4 (en) | 2021-10-20 | 2025-10-22 | Synthekine Inc | HETERODIMERIC FC CYTOKINES AND THEIR USES |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115785204B (zh) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标08及其用途 |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
| CN115747307A (zh) * | 2022-11-03 | 2023-03-07 | 郑州大学 | 一种用于富集检测复发肿瘤细胞的dna水凝胶的制备方法及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025124536A1 (zh) * | 2023-12-15 | 2025-06-19 | 江苏康缘药业股份有限公司 | 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途 |
| CN118166098B (zh) * | 2024-02-05 | 2024-09-10 | 北京大学深圳医院 | 检测magea4-as1的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用 |
| WO2026068511A1 (en) * | 2024-09-24 | 2026-04-02 | Universiteit Gent | Cancer immunotherapy |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
| CN120718855B (zh) * | 2025-09-03 | 2026-02-03 | 天津医科大学总医院 | 一种具有高淋巴结转移潜力的中国人肺大细胞神经内分泌癌细胞系及应用 |
| CN121085997B (zh) * | 2025-11-07 | 2026-03-24 | 青岛农业大学 | 南极磷虾活性肽及其制备方法和应用 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4493795A (en) * | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| JPH07108224B2 (ja) | 1985-11-07 | 1995-11-22 | 重三 鵜高 | バチルス・ブレビスを用いる遺伝子の発現方法 |
| US4772557A (en) * | 1985-11-12 | 1988-09-20 | Washington University | DNA clone of human skin fibroblast collagenase enzyme |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| WO1997000449A1 (en) | 1995-06-14 | 1997-01-03 | Aberdeen University | Prognostic and therapeutic system for cancer |
| US6143509A (en) | 1996-02-06 | 2000-11-07 | Abbott Laboratories | Prostate specific antigen peptides and uses thereof |
| NZ333203A (en) * | 1996-06-07 | 2000-07-28 | Kyogo Itoh | Tumour antigen proteins, genes thereof, and tumour antigen peptides |
| AU4086397A (en) | 1996-09-06 | 1998-03-26 | Centocor Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
| US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US7105488B1 (en) * | 1998-02-27 | 2006-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | G protein-coupled receptor antagonists |
| EP1056778B1 (en) | 1998-02-27 | 2007-12-26 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | G protein-coupled receptor antagonists |
| US6255055B1 (en) | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
| US20030236209A1 (en) * | 1998-03-18 | 2003-12-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
| WO2002034764A1 (en) | 1998-09-28 | 2002-05-02 | Bio Polymer Products Of Sweden Ab | A process of producing polyphenolic adhesive proteins and proteins produced in accordance with the process |
| US20070020327A1 (en) | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| US7259253B2 (en) | 1999-05-14 | 2007-08-21 | Quark Biotech, Inc. | Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| US6869951B1 (en) | 1999-07-16 | 2005-03-22 | Pharmacia Corporation | Method of changing conformation of a matrix metalloproteinase |
| US20020123095A1 (en) | 1999-10-20 | 2002-09-05 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
| US20040142361A1 (en) | 1999-11-30 | 2004-07-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| JP2003517310A (ja) * | 1999-12-10 | 2003-05-27 | エピミューン， インコーポレイテッド | ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導 |
| US20020081590A1 (en) | 2000-02-04 | 2002-06-27 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| WO2001062924A2 (en) | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | Human g protein-coupled receptors |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| US7094890B1 (en) | 2000-03-10 | 2006-08-22 | Novartis Ag | Arthritis-associated protein |
| WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
| US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030073622A1 (en) | 2000-06-07 | 2003-04-17 | Kumud Majumder | Novel proteins and nucleic acids encoding same |
| AU2001268361A1 (en) | 2000-07-07 | 2002-01-21 | Saint Louis University | Method of modulating expression of ldl-receptor-related protein and uses thereof |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US20070014801A1 (en) | 2001-01-24 | 2007-01-18 | Gish Kurt C | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| CA2425648A1 (en) | 2000-10-19 | 2002-04-19 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
| JP2004531228A (ja) | 2000-10-20 | 2004-10-14 | アプレラ コーポレーション | エストロゲン受容体アルファ変異体及びその検出方法 |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040053822A1 (en) | 2000-12-11 | 2004-03-18 | John Fikes | Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| US20030170630A1 (en) | 2000-12-21 | 2003-09-11 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| WO2002068649A2 (en) | 2001-01-31 | 2002-09-06 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20050069976A1 (en) | 2001-02-14 | 2005-03-31 | Peter Lind | Protein-coupled receptor |
| EP1368475A4 (en) * | 2001-03-15 | 2004-10-20 | Nuvelo Inc | NEW NUCLEIC ACIDS AND NEW POLYPEPTIDES |
| US20030077664A1 (en) | 2001-04-18 | 2003-04-24 | Yi Zhao | Methods of screening for compounds that modulate hormone receptor activity |
| JP2005527180A (ja) * | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス， インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
| US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| AU2002330714A1 (en) | 2001-05-30 | 2003-01-02 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
| EP1410013A4 (en) | 2001-06-21 | 2006-02-01 | Millennium Pharm Inc | COMPOSITIONS, KITS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF BREAST AND EGG CANCER |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| CN1547617A (zh) | 2001-06-25 | 2004-11-17 | 2 | 肿瘤学药物革新 |
| US20030108963A1 (en) | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
| JP2003088388A (ja) | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長ｃＤＮＡ |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1430112A4 (en) | 2001-09-24 | 2005-06-15 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| JP2003135075A (ja) | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| WO2003050243A2 (en) | 2001-12-10 | 2003-06-19 | Millennium Pharmaceuticals Inc. | Novel genes encoding colon cancer antigens |
| US6689431B2 (en) | 2001-12-12 | 2004-02-10 | Eastman Kodak Company | Ink jet recording element |
| WO2003063689A2 (en) | 2002-01-29 | 2003-08-07 | Quark Biotech, Inc. | Islr gene and its association with osteoarthritis and other bone and cartilage disorders, expression products derived therefrom, and uses thereof |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| CA2500687A1 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7482117B2 (en) | 2002-12-20 | 2009-01-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| JP2009523404A (ja) | 2003-01-30 | 2009-06-25 | アプレラ コーポレイション | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 |
| DE10309729A1 (de) | 2003-02-26 | 2004-09-16 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Harnblasenkarzinomen |
| US7625699B2 (en) | 2003-03-10 | 2009-12-01 | Celera Corporation | Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof |
| CN1331885C (zh) * | 2003-05-15 | 2007-08-15 | 北京大学 | 肿瘤抗原蛋白及抗原肽在作为肿瘤－睾丸抗原、制备治疗肝癌/肺癌药物中的应用 |
| EP1633865B1 (en) | 2003-06-18 | 2011-09-28 | Bayer Pharma Aktiengesellschaft | New biological entities and the use thereof |
| US20050002897A1 (en) | 2003-06-18 | 2005-01-06 | Ulrich Haupts | Biological entities and the pharmaceutical or diagnostic use thereof |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| EP1749025A2 (en) | 2004-01-27 | 2007-02-07 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer |
| US7569662B2 (en) | 2004-01-27 | 2009-08-04 | Compugen Ltd | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| US7667001B1 (en) | 2004-01-27 | 2010-02-23 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| WO2005084116A2 (en) | 2004-01-27 | 2005-09-15 | Compugen Usa, Inc. | Calcium channel variants |
| CN1930188B (zh) * | 2004-03-10 | 2012-01-11 | 克赖顿大学 | 雌激素受体和使用方法 |
| ATE427499T1 (de) * | 2004-05-21 | 2009-04-15 | Inst Systems Biology | Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen |
| WO2006088483A2 (en) * | 2004-06-16 | 2006-08-24 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the synthesis or expression of mmp-1 |
| WO2006037993A2 (en) | 2004-10-02 | 2006-04-13 | Auvation Limited | Cancer markers |
| DE102005059937A1 (de) | 2004-12-21 | 2006-07-13 | Continental Teves Ag & Co. Ohg | Verfahren zum Betrieb einer hydraulischen Bremsanlage für Kraftfahrzeuge |
| EP1827486A2 (en) | 2004-12-22 | 2007-09-05 | Direvo Biotech AG | Targeted use of engineered enzymes |
| US7883858B2 (en) | 2005-01-27 | 2011-02-08 | Institute For Systems Biology | Methods for identifying and monitoring drug side effects |
| MX2007010349A (es) * | 2005-02-24 | 2008-04-09 | Cemines Inc | Composiciones y metodos para clasificar muestras biologicas. |
| JP4987698B2 (ja) | 2005-03-31 | 2012-07-25 | 中外製薬株式会社 | 癌関連抗原アナログペプチド、およびその利用 |
| US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| EP1806358B1 (en) * | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| WO2007042169A2 (en) * | 2005-10-07 | 2007-04-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
| US20070099251A1 (en) * | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| EP1806413A1 (en) * | 2006-01-06 | 2007-07-11 | Oligene GmbH | An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer |
| US20100120627A1 (en) | 2006-08-02 | 2010-05-13 | Abdelmajid Belouchi | Genemap of the human genes associated with psoriasis |
| JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| CA2674209A1 (en) * | 2006-12-29 | 2008-07-10 | Ipsen Pharma S.A.S. | Glp-1 pharmaceutical compositions |
| US7589662B1 (en) | 2007-06-20 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic aperture radar systems and methods |
| BRPI0813626A2 (pt) | 2007-07-27 | 2014-12-23 | Immatics Biotechnologies Gmbh | Epitopos imunogênicos para a imunoterapia |
| PT2186889E (pt) | 2007-08-20 | 2015-06-17 | Oncotherapy Science Inc | Péptido cdca1 e agente farmacêutico que o compreende |
| WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| WO2009102909A2 (en) * | 2008-02-15 | 2009-08-20 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| JP2011516077A (ja) * | 2008-04-11 | 2011-05-26 | チャイナ シンセティック ラバー コーポレイション | 癌を検出するための方法、薬剤、およびキット |
| RS53872B2 (sr) * | 2008-05-14 | 2018-06-29 | Immatics Biotechnologies Gmbh | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| US20110189694A1 (en) | 2008-10-22 | 2011-08-04 | Biomarker Design Forschungs Gmbh | Methods for detection and diagnosis of a bone or cartilage disorder |
| KR101032860B1 (ko) | 2008-10-22 | 2011-05-06 | 한국식품연구원 | 췌장 조직 특이적 유전자 ｍｍｐ1 |
| CN102307595A (zh) * | 2009-02-10 | 2012-01-04 | 盛诺基医药科技有限公司 | 治疗雌激素受体相关疾病的抗体及方法 |
| WO2010102157A1 (en) * | 2009-03-04 | 2010-09-10 | The Regents Of The University Of California | Molecular predictors of biological response to a cenpe inhibitor in cancer |
| US20110229451A2 (en) | 2009-03-06 | 2011-09-22 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloproteases and uses thereof |
| US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
| US8741581B2 (en) * | 2009-04-27 | 2014-06-03 | Technion Research And Development Foundation Ltd. | Markers for cancer detection |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US20130011496A1 (en) | 2009-11-25 | 2013-01-10 | Ludwig Institute For Cancer Research Ltd. | Cancer testis antigens as biomarkers in non-small cell lung cancer |
| US8680246B2 (en) * | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
| SMT201900495T1 (it) * | 2010-08-17 | 2019-11-13 | Ambrx Inc | Polipeptidi di relaxina modificati e loro usi |
| JP6021021B2 (ja) | 2010-11-05 | 2016-11-02 | 国立大学法人京都大学 | 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 |
| WO2012068210A1 (en) | 2010-11-18 | 2012-05-24 | Janssen Pharmaceutica Nv | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| WO2012094744A1 (en) | 2011-01-11 | 2012-07-19 | University Health Network | Prognostic signature for oral squamous cell carcinoma |
| US20130064901A1 (en) * | 2011-04-18 | 2013-03-14 | Agency For Science, Technology And Research | Gene expression profiling for classifying and treating gastric cancer |
| WO2012162468A1 (en) | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Thiazol derivatives as pro -matrix metalloproteinase inhibitors |
| US20120302569A1 (en) | 2011-05-25 | 2012-11-29 | Paul Francis Jackson | Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| HK1199100A1 (en) | 2011-08-31 | 2015-06-19 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of colorectal cancer |
| US20140274794A1 (en) * | 2011-09-09 | 2014-09-18 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Diagnosis of Ovarian Cancer |
| US9091651B2 (en) | 2011-12-21 | 2015-07-28 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| WO2013147233A1 (ja) | 2012-03-30 | 2013-10-03 | 国立大学法人岡山大学 | 抗体検出用試薬の製造方法、及びその用途 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| GB201208293D0 (en) * | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| DK2895509T3 (da) * | 2012-09-14 | 2020-03-09 | Us Health | T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3 |
| US20160000893A1 (en) | 2012-12-13 | 2016-01-07 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
| WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
| TWI777194B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一） |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| FI3273986T3 (fi) * | 2015-03-27 | 2024-02-07 | Immatics Biotechnologies Gmbh | Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DE102017006829B3 (de) | 2017-07-19 | 2018-09-06 | Daimler Ag | Regalsystem |
| TWI837109B (zh) | 2017-12-28 | 2024-04-01 | 美商磨石生物公司 | 靶向共有抗原之抗原結合蛋白 |
| TW202000907A (zh) | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
| MX2021012004A (es) | 2019-03-30 | 2021-11-04 | Biontech Us Inc | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. |
-
2015
- 2015-03-27 GB GBGB1505305.1A patent/GB201505305D0/en not_active Ceased
-
2016
- 2016-03-23 MA MA041805A patent/MA41805A/fr unknown
- 2016-03-24 CA CA3110160A patent/CA3110160A1/en active Pending
- 2016-03-24 UA UAA201708272A patent/UA124139C2/uk unknown
- 2016-03-24 CA CA3110180A patent/CA3110180A1/en active Pending
- 2016-03-24 CA CA3111096A patent/CA3111096A1/en active Pending
- 2016-03-24 EP EP18174312.1A patent/EP3388077A1/en not_active Withdrawn
- 2016-03-24 CA CA3111059A patent/CA3111059A1/en active Pending
- 2016-03-24 UA UAA201808809A patent/UA123953C2/uk unknown
- 2016-03-24 EP EP18201235.1A patent/EP3456347B1/en active Active
- 2016-03-24 EP EP18174292.5A patent/EP3388076B1/en active Active
- 2016-03-24 EP EP18174251.1A patent/EP3388075B1/en active Active
- 2016-03-24 CA CA3108776A patent/CA3108776A1/en active Pending
- 2016-03-24 CA CA3111740A patent/CA3111740A1/en active Pending
- 2016-03-24 CA CA3111037A patent/CA3111037A1/en active Pending
- 2016-03-24 CN CN202110716733.5A patent/CN113480635A/zh active Pending
- 2016-03-24 CA CA3111077A patent/CA3111077A1/en active Pending
- 2016-03-24 WO PCT/EP2016/056557 patent/WO2016156202A1/en not_active Ceased
- 2016-03-24 CA CA3111648A patent/CA3111648A1/en active Pending
- 2016-03-24 EP EP18174337.8A patent/EP3388079B1/en active Active
- 2016-03-24 BR BR112017017289-5A patent/BR112017017289A2/en not_active Application Discontinuation
- 2016-03-24 CA CA3109693A patent/CA3109693A1/en active Pending
- 2016-03-24 EA EA201891699A patent/EA201891699A3/ru unknown
- 2016-03-24 SG SG11201706681VA patent/SG11201706681VA/en unknown
- 2016-03-24 CA CA3111621A patent/CA3111621A1/en active Pending
- 2016-03-24 MA MA043436A patent/MA43436A/fr unknown
- 2016-03-24 KR KR1020217011039A patent/KR20210043752A/ko not_active Ceased
- 2016-03-24 EP EP16711659.9A patent/EP3273986B1/en active Active
- 2016-03-24 MA MA043437A patent/MA43437A/fr unknown
- 2016-03-24 CA CA3111633A patent/CA3111633A1/en active Pending
- 2016-03-24 CN CN201680018847.XA patent/CN107531754B/zh not_active Expired - Fee Related
- 2016-03-24 CA CA3111899A patent/CA3111899A1/en active Pending
- 2016-03-24 CA CA3111739A patent/CA3111739A1/en active Pending
- 2016-03-24 CA CA3112078A patent/CA3112078A1/en active Pending
- 2016-03-24 CA CA3109690A patent/CA3109690A1/en active Pending
- 2016-03-24 CR CR20200471A patent/CR20200471A/es unknown
- 2016-03-24 CA CA2980805A patent/CA2980805A1/en active Pending
- 2016-03-24 MA MA40813A patent/MA40813A1/fr unknown
- 2016-03-24 PE PE2017001462A patent/PE20171442A1/es unknown
- 2016-03-24 KR KR1020177027189A patent/KR20170129787A/ko not_active Ceased
- 2016-03-24 CA CA3110245A patent/CA3110245A1/en not_active Abandoned
- 2016-03-24 JP JP2017549616A patent/JP6882985B2/ja not_active Expired - Fee Related
- 2016-03-24 CA CA3111891A patent/CA3111891A1/en active Pending
- 2016-03-24 EA EA201791925A patent/EA039163B1/ru unknown
- 2016-03-24 CA CA3111741A patent/CA3111741A1/en active Pending
- 2016-03-24 SG SG10201806839PA patent/SG10201806839PA/en unknown
- 2016-03-24 MA MA043438A patent/MA43438A/fr unknown
- 2016-03-24 KR KR1020187023154A patent/KR102251606B1/ko not_active Expired - Fee Related
- 2016-03-24 MA MA43435A patent/MA43435B1/fr unknown
- 2016-03-24 MA MA044999A patent/MA44999A/fr unknown
- 2016-03-24 MX MX2017012427A patent/MX2017012427A/es unknown
- 2016-03-24 CA CA3111881A patent/CA3111881A1/en active Pending
- 2016-03-24 EA EA202191027A patent/EA202191027A3/ru unknown
- 2016-03-24 MA MA043440A patent/MA43440A/fr unknown
- 2016-03-24 CR CR20180422A patent/CR20180422A/es unknown
- 2016-03-24 CA CA3112084A patent/CA3112084A1/en active Pending
- 2016-03-24 AU AU2016239920A patent/AU2016239920B2/en not_active Ceased
- 2016-03-24 CA CA3111203A patent/CA3111203A1/en active Pending
- 2016-03-24 EP EP18174354.3A patent/EP3388080B1/en active Active
- 2016-03-24 EP EP18174323.8A patent/EP3388078B1/en active Active
- 2016-03-24 CA CA3110241A patent/CA3110241A1/en active Pending
- 2016-03-24 CR CR20200478A patent/CR20200478A/es unknown
- 2016-03-24 SG SG10202001485UA patent/SG10202001485UA/en unknown
- 2016-03-24 CA CA3111194A patent/CA3111194A1/en active Pending
- 2016-03-24 CA CA3111744A patent/CA3111744A1/en active Pending
- 2016-03-24 MA MA043439A patent/MA43439A/fr unknown
- 2016-03-28 US US15/082,986 patent/US9988432B2/en active Active
- 2016-03-28 US US15/082,999 patent/US10081665B2/en active Active
- 2016-03-28 US US15/082,967 patent/US10072063B2/en active Active
- 2016-03-28 US US15/083,139 patent/US10336809B2/en active Active
- 2016-03-28 US US15/083,106 patent/US9802997B2/en active Active
- 2016-03-28 US US15/082,948 patent/US10081664B2/en active Active
- 2016-03-28 TW TW109124266A patent/TW202043258A/zh unknown
- 2016-03-28 US US15/082,962 patent/US20160279215A1/en not_active Abandoned
- 2016-03-28 US US15/083,075 patent/US10000547B2/en active Active
- 2016-03-28 TW TW105109711A patent/TWI721971B/zh not_active IP Right Cessation
- 2016-03-28 US US15/082,933 patent/US9932384B2/en not_active Expired - Fee Related
- 2016-03-28 TW TW107128267A patent/TWI722311B/zh not_active IP Right Cessation
- 2016-03-28 US US15/083,035 patent/US20160279218A1/en not_active Abandoned
- 2016-03-28 US US15/082,978 patent/US20160279216A1/en not_active Abandoned
- 2016-11-28 US US15/362,274 patent/US9840548B2/en not_active Expired - Fee Related
- 2016-11-28 US US15/362,294 patent/US9982030B2/en active Active
- 2016-11-28 US US15/362,281 patent/US9862756B2/en not_active Expired - Fee Related
-
2017
- 2017-06-30 US US15/638,667 patent/US9994628B2/en active Active
- 2017-06-30 US US15/638,687 patent/US9951119B2/en active Active
- 2017-06-30 US US15/638,678 patent/US20170305992A1/en not_active Abandoned
- 2017-10-20 US US15/789,750 patent/US20180037628A1/en not_active Abandoned
- 2017-10-20 US US15/789,683 patent/US10766944B2/en active Active
- 2017-10-20 US US15/789,589 patent/US9982031B2/en active Active
- 2017-10-20 US US15/789,731 patent/US10059755B2/en active Active
- 2017-10-20 US US15/789,771 patent/US10370429B2/en active Active
- 2017-10-20 US US15/789,567 patent/US10138288B2/en active Active
- 2017-12-14 US US15/842,381 patent/US10005828B2/en active Active
- 2017-12-19 US US15/847,825 patent/US10501522B2/en active Active
-
2018
- 2018-03-09 US US15/917,159 patent/US10202436B2/en active Active
- 2018-03-13 US US15/919,984 patent/US10131703B2/en active Active
- 2018-04-12 US US15/951,789 patent/US10183982B2/en active Active
- 2018-04-13 US US15/953,128 patent/US10066003B1/en active Active
- 2018-04-18 US US15/956,641 patent/US10106593B2/en active Active
- 2018-04-18 US US15/956,638 patent/US10093715B2/en active Active
- 2018-05-03 US US15/970,194 patent/US20180251517A1/en not_active Abandoned
- 2018-05-04 US US15/971,799 patent/US10106594B2/en active Active
- 2018-05-10 US US15/976,621 patent/US10519215B2/en not_active Expired - Fee Related
- 2018-07-24 US US16/044,289 patent/US10155801B1/en active Active
- 2018-07-24 US US16/044,266 patent/US20180327475A1/en not_active Abandoned
- 2018-08-06 US US16/055,796 patent/US10934338B2/en not_active Expired - Fee Related
- 2018-09-10 US US16/126,663 patent/US10487131B2/en active Active
- 2018-09-19 AU AU2018232952A patent/AU2018232952C1/en not_active Ceased
- 2018-10-04 US US16/152,122 patent/US10479823B2/en active Active
- 2018-12-20 US US16/227,257 patent/US20190119352A1/en not_active Abandoned
- 2018-12-20 US US16/227,228 patent/US10450362B2/en active Active
-
2019
- 2019-03-06 US US16/293,749 patent/US20190185540A1/en not_active Abandoned
- 2019-04-12 AU AU2019202561A patent/AU2019202561B2/en not_active Ceased
- 2019-09-02 AU AU2019222976A patent/AU2019222976B2/en not_active Ceased
- 2019-10-02 US US16/591,083 patent/US11466072B2/en active Active
- 2019-10-02 US US16/590,933 patent/US10723781B2/en active Active
- 2019-10-02 US US16/591,177 patent/US11702460B2/en active Active
- 2019-11-12 US US16/681,363 patent/US11155597B2/en active Active
-
2020
- 2020-06-12 US US16/900,542 patent/US10947293B2/en not_active Expired - Fee Related
- 2020-06-24 US US16/911,066 patent/US10947294B2/en not_active Expired - Fee Related
- 2020-10-12 AU AU2020256298A patent/AU2020256298B2/en not_active Ceased
-
2021
- 2021-02-10 US US17/172,621 patent/US11897934B2/en active Active
- 2021-02-10 US US17/172,577 patent/US11873329B2/en active Active
- 2021-02-18 US US17/179,074 patent/US12060406B2/en active Active
- 2021-06-18 AU AU2021204078A patent/AU2021204078B2/en not_active Ceased
- 2021-06-18 AU AU2021204077A patent/AU2021204077B2/en not_active Ceased
- 2021-06-18 AU AU2021204074A patent/AU2021204074B2/en not_active Ceased
- 2021-06-18 AU AU2021204081A patent/AU2021204081B2/en not_active Ceased
- 2021-06-18 AU AU2021204076A patent/AU2021204076B2/en not_active Ceased
- 2021-06-18 AU AU2021204075A patent/AU2021204075B2/en not_active Ceased
- 2021-06-18 AU AU2021204080A patent/AU2021204080B2/en not_active Ceased
- 2021-06-18 AU AU2021204079A patent/AU2021204079B2/en not_active Ceased
- 2021-07-23 US US17/384,330 patent/US11407807B2/en active Active
-
2022
- 2022-09-21 AR ARP220102547A patent/AR127116A2/es not_active Application Discontinuation
- 2022-09-21 AR ARP220102550A patent/AR127119A2/es not_active Application Discontinuation
- 2022-09-21 AR ARP220102549A patent/AR127118A2/es not_active Application Discontinuation
- 2022-09-21 AR ARP220102548A patent/AR127117A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518937A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2018521641A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2021514178A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2017525336A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2022105069A5 (enExample) | ||
| JP2020530759A5 (enExample) | ||
| JP2018519825A5 (enExample) | ||
| JP2021535900A5 (enExample) | ||
| JP2017524337A5 (enExample) |